TKT and urinary bladder carcinoma: The HSV-TK displayed a 1000-fold higher affinity for its substrate GCV than the mammalian TK, and this targeting design could reduce the unwanted HSV-TK activity in other non-bladder cancer tissues, which limits systemic toxicity.